Researchers have achieved a breakthrough in AI opioid relapse prediction by analysing smartphone data from people receiving treatment for opioid use disorder. The technology forecasted relapse risk with exceptional accuracy, opening possibilities for proactive interventions.

Over six months, more than 60 people receiving medication-assisted treatment answered surveys on their smartphones three times daily. Questions covered their mental health, psychological state, and environment.

When deep learning models analysed their responses, the artificial intelligence technology demonstrated remarkable predictive capabilities. The study was published in the Journal of Substance Use and Addiction Treatment in June 2025.

High Accuracy in Next-Day Relapse Forecasting

The National Institutes of Health-funded study included researchers from New Hampshire, New York, California, Massachusetts, and Maryland. They found AI using real-time monitoring has potential to serve as a strong predictive tool and early-warning system.

The technology could pave the way for proactive, personalised interventions. This would prove particularly valuable when someone in active treatment may be teetering on the edge, the study indicates.

Pairing daily smartphone surveys with AI-based prediction models resulted in high accuracy for assessing next-day opioid relapse, the researchers determined. Real-time predictions can be relayed to clinicians and recovery supports, giving them opportunities to intervene when someone faces risk.

“Our work is the first to use personalised, naturalistic features to predict clinically relevant outcomes in persons receiving medications for opioid use disorder,” the study’s authors wrote. They noted the “considerable public health importance” of their findings, given challenges associated with successful, ongoing treatment for those struggling with drug addiction.

Key Predictive Factors for AI Opioid Relapse Prediction

Influential factors considered by the deep learning models included several crucial indicators. Past-hour substance use emerged as the strongest indicator that someone would use the next day.

Situational risk factors also proved highly predictive. These included seeing drugs or being near substances. Mood indicators, particularly boredom and exhaustion, successfully signalled increased risk.

Difficulty with self-regulation featured prominently in the analysis. Social and environmental contexts surrounding the individual also contributed to prediction accuracy.

Being in high-risk environments where substances were present successfully signalled increased risk for opioid relapse within hours, the study found. Stress and pain forecasted relapse risk several days in advance, potentially giving clinicians a valuable window of time to intervene and offer support.

Study Methodology and Data Collection

The study centred on 62 adults receiving buprenorphine at an outpatient addiction treatment clinic in California. The research took place between June 2020 and January 2021.

Buprenorphine is a prescription medication used to treat opioid use disorder. Participants answered smartphone surveys three times daily throughout the six-month period.

In total, 14,322 observations from the daily smartphone surveys were collected. This substantial dataset enabled the deep learning models to identify patterns and predictive indicators.

Perhaps the most obvious predictor: participants were found most likely to relapse the next day if they had self-reported substance use in the past hour. Situational risk factors such as triggers like stress or seeing drugs, as well as boredom, exhaustion, low contentment, or inability to plan or follow through, were also strong indicators.

Broader Context of Opioid Use Disorder

Among the five to seven million people estimated to have an opioid use disorder nationally in the United States, the US Food and Drug Administration estimates relapse rates of 65 to 70 percent.

These staggering statistics underscore the importance of developing better predictive tools and intervention strategies. Traditional treatment approaches often respond reactively after relapse has occurred. AI opioid relapse prediction technology offers potential for preventative action.

AI Integration in Addiction Treatment

Just as artificial intelligence is being integrated into the broader healthcare landscape, it’s also making itself known in addiction medicine and treatment.

In April 2025, a National Institutes of Health-supported clinical trial found AI tools can be as effective as healthcare providers in generating referrals to addiction specialists.

Researchers at Dartmouth College have trained AI models to analyse Reddit posts where users discussed their experiences with opioid use disorder treatment. This demonstrates the technology’s versatility in gathering insights from diverse data sources.

AI-powered chatbots are also being developed to serve as recovery supports. These digital tools can provide round-the-clock assistance to individuals navigating recovery.

“It’s crucial to understand that (AI) is not intended to replace human therapists,” Caroline Easton, academic division chief of addiction psychiatry at the University of Rochester Medical Centre, explained in an interview. “Instead, it supports them. AI can help reduce therapists’ workloads, minimise compassion fatigue and burnout, and provide additional resources for patient care.”

Controversies and Concerns

Many controversies surround the implementation of artificial intelligence in healthcare globally. Concerns include data privacy, potential inaccuracies, and the perceived replacement of trained physicians and medical staff.

Brenda Curtis, a researcher at the National Institute of Drug Abuse, has acknowledged “trepidation” about potential AI uses. However, she said her field is “taking a hard look at things.”

“(We) can have a voice in using and improving technology,” Curtis said. “We can use it to dispense large amounts of information quickly, and we can use it to help treatment and healthcare be more efficient and effective.”

Study Limitations Acknowledged

Researchers acknowledged limitations in the study combining artificial intelligence and smartphone data. Most notably, predictive models are not always accurate.

The study yielded both false positives and false negatives. The sample size was described as “modest” with limited demographic diversity.

Deep learning models trained on predominantly white populations in a certain geographic area might misinterpret behaviours or health indicators from other racial or ethnic groups. This represents an example of how AI can reflect, or in some cases amplify, already existing disparities.

The AI models weren’t as accurate in forecasting whether a patient might skip their buprenorphine medication. This suggests the technology performs better for some predictions than others.

Practical Applications and Future Potential

The real-time nature of AI opioid relapse prediction represents its most compelling advantage. Traditional clinical assessments typically occur during scheduled appointments, potentially missing critical warning signs between sessions.

Smartphone-based monitoring paired with artificial intelligence enables continuous assessment. Clinicians can receive alerts when predictive models identify elevated risk, allowing timely intervention.

This could include reaching out to check on the patient, adjusting medication, providing additional counselling sessions, or connecting them with peer support. The goal is preventing relapse before it occurs rather than responding after the fact.

Predictive Windows Offer Intervention Opportunities

Different predictive factors operated on different timescales, the research revealed. Mood predictors like boredom and exhaustion, combined with being in high-risk environments, signalled increased risk within hours.

This provides an immediate window for intervention. Clinicians or support systems could respond quickly when these indicators appear.

Stress and pain, conversely, forecasted relapse risk several days in advance. This longer predictive window offers opportunities for more comprehensive intervention planning and support mobilisation.

Balancing Technology and Human Care

The integration of AI opioid relapse prediction technology into addiction treatment raises important questions about the balance between technological tools and human connection.

Recovery from substance use disorders fundamentally relies on human relationships, trust, and compassion. Technology should enhance rather than replace these essential elements.

Easton’s emphasis that AI supports rather than replaces human therapists reflects growing consensus in the field. The technology handles data analysis, pattern recognition, and alert generation. Human clinicians provide empathy, clinical judgement, and therapeutic relationships.

Data Privacy Considerations

The collection of detailed, personal information three times daily raises legitimate privacy concerns. Participants share information about their mental health, substance use, environmental contexts, and daily experiences.

Robust data protection measures become essential when implementing such monitoring systems. Participants must understand how their data will be used, stored, and protected.

The trade-off between privacy and predictive capability requires careful ethical consideration. Individuals in recovery must feel comfortable sharing accurate information without fear of judgement or negative consequences.

Path Forward for Implementation

Moving from research findings to clinical implementation presents numerous challenges. Healthcare systems must develop infrastructure to support continuous monitoring and real-time response.

Clinicians require training on interpreting AI-generated alerts and incorporating them into treatment planning. Insurance coverage and reimbursement structures need adaptation to support this monitoring approach.

Despite these challenges, AI opioid relapse prediction technology represents a promising tool in addressing the ongoing substance use crisis. As the technology matures and systems adapt, it could become standard practice in addiction treatment settings.

The study’s findings demonstrate that combining personal data, real-time monitoring, and artificial intelligence can predict relapse risk with meaningful accuracy. This opens new possibilities for preventing relapse rather than simply responding to it.

Source: MassLive